Since 1982, scientists have conducted extensive preclinical research on molecular-targeted therapies for sepsis, including corticosteroids, TLR4 receptor antagonists, anti-TNF-α agents, and interventions targeting cytotoxic effects and the coagulation cascade. The gene discussed is TNF; the disease is Sepsis.